The new findings were presented May 11, 2012, at the World Congress of Brachytherapy, held in Barcelona (Spain). Dr. Renaud Mazeron reported that a review of the use of 3D image-guided adaptive brachytherapy (IGABT) after a course of chemotherapy and radiotherapy administered together (concomitant chemoradiation) in 163 patients treated between 2004-2009 at the Institut Gustave Roussy (Villejuif, France), had shown that it achieved results that were far superior to those from earlier times using different treatments. Not only was IGABT effective at controlling the tumor, but it also had more acceptable side effects.
At present there is no conclusive evidence whether or not women with cervical cancer, particularly if it is at an advanced stage (stage IB-IIB), should have their wombs removed to help to avoid the cancer returning or spreading. This study suggests that hysterectomies may be unnecessary for most women, unless the cancer has obviously returned and invaded the womb.
Dr. Mazeron, who is an assistant professor in the radiation oncology department of the Institut Gustave Roussy, said, “IGABT is a three-dimensional technique of brachytherapy allowing a much better adaptation of treatment to the target area, while preserving healthy organs at risk from radiation. Our department has been one of the pioneers of this technique and we already have accumulated significant experience. Our current study does not formally show that surgery is unnecessary, since we did not conduct a randomized comparison, but it shows that IGABT combined with chemoradiation achieves results far superior to the historical data, with high rates of control at the site of the primary tumor. In our institute, surgeons have been convinced to abandon systematic surgery by the advances in concomitant chemoradiation and IGABT, and the conjunction of both. Historic data based on classical techniques, which gave external radiation without chemotherapy and X-ray-based brachytherapy which did not allow to adapt the treatment to each case, show that local control of a stage I tumor was usually around 90%, between 60%-87% for stage II, 44%-66% for stage III, and 18%-48% for stage IVA. In this study, we report a rate of 92% in a large group of patients with tumors at any stage.”
Of the 163 patients in the study, 27% had stage I cervical cancer, 57% stage II, 12% stage III, and 3% stage IV. They received concomitant chemoradiation followed by brachytherapy that was guided to the correct area by either magnetic resonance imaging (MRI) in 88% of cases, or computed tomography (CT) in 12% of cases.
Sixty-one (37%) of the women underwent a radical hysterectomy, but residual cancer cells were found in only 13 of these cases. Dr. Mazeron reported that the operations were partly because the study covered a crucial period when surgeons ceased to operate regularly on cervical cancer patients. “At present, surgery is proposed in case of obvious residual tumor after chemoradiation and IGABT. It is sometimes difficult to define complete remission, and thus some patients in the study were operated due to clinical or imaging suspicion of residual tumor, but finally were found to be in complete pathological remission. Currently, surgeons at our institute practice radical hysterectomy following chemoradiotherapy and IGABT only a few times per year, after a biopsy has confirmed that part of the tumor remains. However, in another study, we have shown a worse prognosis, despite surgery, for patients who do not respond completely to radiotherapy or brachytherapy due to a higher risk of metastases,” he said.
After an average follow-up of 36 months, 45 patients had relapsed, including one woman who had had a hysterectomy, and of whom 70.4% had distant metastases. “This clearly shows that distant metastases are the primary cause of relapse,” said Dr. Mazeron.
After three years, overall survival and disease-free survival was 84% and 73%, respectively. Control of the tumor at its primary site (local control) decreased in relation to the initial width of the tumor: 97% for less than 5 cm, 91% for 5-6 cm and 81% for 6 cm or more. Only 7.4% of patients experienced more severe side effects (grade 3/4), but of these 12 patients, nine had undergone a hysterectomy after radiotherapy. “This represents a strong argument for not performing surgery in patients in complete remission after treatment with concomitant chemoradiation and IGABT,” said Dr. Mazeron.
According to Dr. Mazeron, IGABT was an emerging technology and the results from this study should be validated by two international studies, one of which will be presented at the parallel ESTRO 31 conference. “IGABT is the future of brachytherapy in cervical cancer. Potential financial investments should not discourage radiation oncologists. It costs less than intensity-modulated radiation therapy [IMRT], a technique of external beam radiotherapy that has become a standard in the treatment of some cancers. We must keep in mind that cervical cancer is a public health problem in developing countries where it is the second most common cancer in women following breast cancer. IGABT represents a significant improvement in results, and some centers are already practicing this technique in India and Southeast Asia,” he concluded.
Dr. Christine Haie-Meder, radiation oncologist at the Institut Gustave Roussy and chairperson of the World Congress of Brachytherapy, commented, “Image-guided adaptive brachytherapy has recently been implemented in cervix cancer patients. Results are in favor of a significant improvement in local control. The present series also contribute to show improvement in local control with IGABT. Within this context, complementary surgery does not bring any further contribution to local control improvement, and hysterectomy may even increase the risk of complications.”
Brachytherapy is a type of internal radiotherapy, which involves putting solid radioactive material close to, or inside, the tumor. This gives a high dose of radiotherapy directly to the tumor but only a low dose to normal tissues.
The World Congress of Brachytherapy was held in parallel with the 31st conference of the European Society for Radiotherapy and Oncology (ESTRO 31), both took place in Barcelona (Spain), during May 9-13, 2012.
Source:
medimaging.net
